Lable of difenoconazole 美国公司

农业部公告第1206号――关于给4家外国公司核发《进口兽药注册证书》的公告正文：---------------------------------------------------------------------------------------------------------------------------------------------------- 农业部公告（第1206号）根据《兽药管理条例》和《兽药注册办法》规定，经审核，批准美国富道动物保健公司生产的猫鼻气管炎、嵌杯病毒病、泛白细胞减少症三联灭活疫苗在我国注册，现核发《进口兽药注册证书》，并发布质量标准、标签和说明书，自发布之日起执行。

批准以色列雅贝克药物与化学工业有限公司等4家公司生产的癸甲溴铵溶液等4种兽药产品在我国再注册，现核发《进口兽药注册证书》。

兽药质量标准执行我部已发布的同品种进口兽药质量标准。

批准以色列雅贝克药物与化学工业有限公司生产的烟酸诺氟沙星在我国再注册，现核发《进口兽药注册证书》。

兽药质量标准执行农业部第307号公告中同品种兽药质量标准，原发布的同品种进口兽药质量标准同时废止。

批准德国罗曼动物保健有限公司等2家公司生产的鸡传染性法氏囊病活疫苗等4种兽药产品在我国再注册，现核发《进口兽药注册证书》，并发布修订后的质量标准、标签和说明书，自发布之日起执行。

原发布的同品种进口兽药质量标准、标签和说明书同时废止。

特此公告附件：1．进口兽药注册目录2．质量标准（略）3．标签和说明书（略）二〇〇九年五月十三日附件1：进口兽药注册目录兽药名称生产厂家证书号有效期限备注猫鼻气管炎、嵌杯病毒病、泛白细胞减少症三联灭活疫苗Feline Rhinotracheitis，Calicivirus，Panleukopenia Vaccine，Inactivated（Fel-O-Vax Pct）美国富道动物保健公司Fort Dodge Animal Health （2009）外兽药证字2 3号2009.05-2014.04注册癸甲溴铵溶液Deciquam Solution（Bromosept）以色列雅贝克药物与化学工业有限公司ABIC LTD．Pharmaceutical &Chemical Industries（2009）外兽药证字24号2009.05-2014.04再注册非泼罗尼喷剂Fipronil?Spray梅里亚有限公司法国生产厂Merial SAS．France（2009）外兽药证字25号2009.05-2014.04再注册氨基丁三醇前列腺素F2a注射液Prostaglandin F2a Tromethamine Injection（LUTALYSE）法玛西亚比利时生产广Pharmacia NV／SA（2009）外兽药证字26号2009.05-2014.04再注册烟酸诺氟沙星Norfloxacin Nicotinate（QUINABIC）以色列雅贝克药物与化学工业有限公司ABIC LTD．Pharmaceutical &Chemical Indus～ies（2009）外兽药证字27号2009.05-2014.04再注册鸡马立克氏病活疫苗（CVl988／Ri spens株）Marek’S Disease Vaccine，Live （Strain CVl988／Rispens）（AviPro～MDRISPENSIlL）德国罗曼动物保健有限公司Lohmann Animal HealthGmbH&Co．KG（2009）外兽药证字28号2009.05-2014.04再注册鸡传染性法氏囊病活疫苗（LC75株）Infectious Bursal Disease Vaccine，Live（Strain LC75）（AviPro～PRECISE）德国罗曼动物保健有限公司Lohmann Animal HealthGmbH＆Co．KG（2009）外兽药证字29号2009.05-2014.04再注册替米考星预混剂Tilmicosin Premix（Pulmotil）礼来公司英国生产厂Eli Lilly and Company Limited（2009）外兽药证字30号2009.05-2014.04再注册甲基盐霉素预混剂Narasin Premix（Monteban?1 00）礼来公司美国生产厂A Division of Eli Lillyand Company U．S．A．（2009）外兽药证字3l号2009.05-2014.04再注册三氯苯达唑混悬液Triclabendazole Suspension （Fasinex）诺华公司英国Vericore生产厂Vericore Limited （2009）外兽药证字32号2009.05-2014.04再注册——结束——。

美国FDA要求增加非典型抗精神病药物说明书中的警告内容张燕
【期刊名称】《中国药物警戒》
【年(卷),期】2004(1)2
【总页数】1页(P60-60)
【关键词】美国FDA;非典型抗精神病药物;说明书;警告内容
【作者】张燕
【作者单位】
【正文语种】中文
【中图分类】R971.4;R95
【相关文献】
1.美国FDA强制要求含壬苯醇醚9的OTC避孕药添加新警告语——说明书中必须警示消费者此类产品不能预防性病和艾滋病 [J], 訾鹏（摘译）
2.FDA要求在氟喹诺酮类药品说明书中增加加框警示 [J],
3.美国FDA要求两种湿疹药膏增加“最强癌症风险”警告说明 [J],
4.土耳其卫生部要求增加塞来昔布说明书中的警告内容 [J], 王丹
5.FDA要求增加非典型抗精神病药物标签中的警告内容 [J],
因版权原因，仅展示原文概要，查看原文内容请购买。

美国FDA分析方法验证指南中英文对照2012-03-05 10:37I. INTRODUCTIONThis guidance provides recommendations to applicants on submitting analytical procedures, validation data, and samples to support the documentation of the identity, strength, quality, purity, and potency of drug substances and drug products.1. 绪论本指南旨在为申请者提供建议，以帮助其提交分析方法，方法验证资料和样品用于支持原料药和制剂的认定，剂量，质量，纯度和效力方面的文件。

This guidance is intended to assist applicants in assembling information, submitting samples, and presenting data to support analytical methodologies. The recommendations apply to drug substances and drug products covered in new drug applications (NDAs), abbreviated new drug applications (ANDAs), biologics license applications (BLAs), product license applications (PLAs), and supplements to these applications.本指南旨在帮助申请者收集资料，递交样品并资料以支持分析方法。

这些建议适用于NDA，ANDA，BLA，PLA及其它们的补充中所涉及的原料药和制剂。

美国FDA批准新型外用药物多杀菌素用于治疗头虱感染
佚名
【期刊名称】《中国执业药师》
【年(卷),期】2011(8)3
【摘要】ParaPro制药公司的新药多杀菌素（通用名为Spinosad，商品名为Natroba）于2011年1月18日获得美国FDA的批准上市，该药作为新型的外
用药物，将用于治疗4岁以上患者冈头虱引起的感染。

【总页数】1页(P53-53)
【关键词】美国FDA;头虱感染;外用药物;杀菌素;FDA批准;治疗;制药公司;批准上
市
【正文语种】中文
【中图分类】R95
【相关文献】
1.Bard公司一级召回Composix(R) Kugel Mesh贴片的最新信息/Ligand公司发布地尼白介素2的重要药物警告/美国FDA批准多西他赛用于治疗晚期胃癌/抗癫痫药噻加宾有望治疗焦虑和抑郁症/脂联素与1型糖尿病患者肾功能呈逆相关/严格控制血糖可改善1型糖尿病患者的左心室功能 [J],
2.美国FDA批准治疗头虱药物Sklice(ivermectin/伊维菌素)由处方药转为非处方药 [J], 夏训明(编译)
3.美国FDA批准Nurtec ODT作为可用于急性治疗/预防性治疗的偏头痛药物 [J],
4.FDA批准辉瑞公司的口服头孢菌素用于治疗犬皮肤感染的申请 [J],
5.美国FDA批准Natroba用于治疗头虱感染 [J], 夏训明
因版权原因，仅展示原文概要，查看原文内容请购买。

CANBERRA CORPORATIONSAFETY DATA SHEET1. IdentificationProduct Identifier: SANITIZER/VIRUCIDAL HUSKY 803 S/V DISINFECTANTApplication or recommended use: Concentrated hard surface sanitizer/disinfectantRestrictions on use: Do not use in any fashion not specified on the product label.Manufacturer / supplier: Canberra Corporation3610 N. Holland-Sylvania Rd.Toledo, Ohio 43615 USATelephone: 419-841-6616Emergency phone: 800-832-8992 National Poison Center: 800-222-12222. Hazards IdentificationGHS Classification: Classification of this mixture in accordance with paragraph (d) of §1910.1200.Skin Corrosion/Irritation - Category 1CEye Damage/Irritation - Category 1Labeling:Symbol:Signal word: DANGERHazard statements: Causes severe skin burns and serious eye damage.Precautionary statements: Do not breathe mist/vapors/spray.Wash hands, face and any skin contact thoroughly after handling.Wear protective gloves/protective clothing/eye protection/face protection.IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin withwater/shower. Wash contaminated clothing before reuse.IF INHALED: Remove person to fresh air and keep comfortable for breathing.IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if presentand easy to do. Continue rinsing.Immediately call a POISON CENTER or doctor/physician.See 4. First-Aid Measures for specific treatment.Store locked up.Dispose of contents/container to an approved disposal facility.Other Hazards: Harmful if swallowed.3. Composition / Information on IngredientsChemical characterization: Concentrated mixture of water, germicides and auxiliary agents.Hazardous ingredients:4.5% Dialkyl dimethyl ammonium chlorides CAS 68424-95-3, EINECS/ELINCS 270-331-53.0% Alkyl dimethylbenzyl ammonium chlorides CAS 68424-85-1, EINECS/ELINCS 270-325-2Other ingredients (> 1%):> 90% Water CAS 7732-18-5, EINECS/ELINCS4. First-Aid MeasuresSymptoms: Burning or irritation of affected areas. Causes severe skin burns and serious eye damage. Have the product container or label with you when calling a poison control center or doctor, or going for treatment.Inhalation: Move person to fresh air. If person is not breathing, call 911 or an ambulance, then give artificial respiration, preferably by mouth-to-mouth to an unconscious person. If respiratory irritation, dizziness, or unconsciousness occurs, seek immediate medical assistance.Skin (Hair) Contact: Remove contaminated clothing and wash before reuse. Wash contaminated area with soap and water for 15-20 minutes. Call a poison control center or doctor for treatment advice.Eye Contact: Hold eye open and rinse slowly and gently with water for 15-20 minutes. Remove contact lenses, if present, after first 5 minutes, then continue rinsing eye. Call a poison control center or doctor for treatment advice.4. First-Aid Measures (cont.)Ingestion: Call a poison control center or doctor immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or doctor. Do not give anything by mouth to a person who is unconscious or convulsing. If vomiting occurs, keep head below hips to reduce risk of aspiration. Probable mucosal damage may contraindicate the use of gastric lavage.Note to Physician: Treat exposed patients symptomatically.5. Fire-Fighting MeasuresSuitable Extinguishing Media: Not applicable. Product is not a fire hazard.Unsuitable Extinguishing Media: High pressure water jet. Specific hazards in case of fire: None known. Special Fire Fighting Precautions: Fire fighters should wear appropriate protective equipment, including self-contained breathing apparatus and impervious clothing.6. Accidental Release MeasuresEmergency Procedures: Depending on the extent of release, consider the need for restriction of access to spill area. Personal Precautions: Do not eat, drink or smoke during clean up. Wear protective clothing, eye protection and impervious gloves (e.g. neoprene). Wash thoroughly after clean up.Environmental Precautions: Prevent spills from entering storm sewers/drains or contact with soil.Clean up Methods: Small spills may be wiped up and rinsed with water. For larger spills, contain spill with inert material (sand, clay). Transfer material to labeled containers for recovery or proper disposal. After removal, flush area with water. Follow good industrial hygiene practices.7. Handling and StoragePrecautions for Safe Handling: Read label before use. Avoid contact with skin or eyes. Do not breathe mist/vapors. Wash hands, face and any skin contact thoroughly after handling. Do not eat, drink or smoke when using this product. Wear protective gloves, protective clothing, eye protection, face protection. Use product only according to label directions. If unsure about safe use, contact your supervisor.Conditions for Safe Storage: Keep out of reach of children. Do not contaminate water, food or feed by storage and disposal. Store locked up in tightly closed, original contain er in a cool (10˚ - 30˚C), dry area.Incompatibility: Anionic detergents inactivate material.8. Exposure Controls / Personal ProtectionComponents with occupational exposure limits: NoneEngineering Controls: Proper ventilation in accordance with good industrial hygiene should be provided.Personal Protective EquipmentRespiratory: Respiratory protection is not necessary under normal conditions of use.Gloves: Use water impervious gloves (latex or neoprene rubber). No breakthrough time has been established.Eye Protection: Chemical resistant goggles or face protection.Other: Protective clothing (long sleeves, pants), eyewash, safety shower are always advisable when working with chemicals.9. Physical and Chemical PropertiesPhysical State - Liquid Auto-ignition temperature - Not applicableColor - None Flash Point - NoneOdor - Quaternary Ammonium Flammability - Not applicableOdor Threshold - No data available Flammability Limits - Not applicableBoiling Point - 212°F Partition coefficient - Not applicableDecomposition temperature - No data available Solubility (Water) - CompleteFreezing Point - 32°F Vapor Density - No data availablepH (Conc.) - 6.0 - 7.0 Vapor Pressure - No data availablepH (RTU) - 6.0 - 7.0 Viscosity - Slightly viscousRelative Density - 1.000 % VOC - < 1 (Excluding exempt material) Evaporation Rate -Similar to water10. Stability and ReactivityReactivity: No specific reactivity test data is available for this mixture. Under normal conditions of storage and use, hazardous reactions are not expected. Incompatible materials: Oxidizers, anionic detergents.Chemical stability: This product is stable at ambient temperatures and pressures.Conditions to avoid: Temperatures above 50°C or below 10°C.Hazardous decomposition products: None known11. Toxicological InformationAcute Toxicity: Toxicity data is not available for this mixture. Data below are estimates based on summation methods.Test Results Classification (A.0.4.1(c)) Basis (A.1.3.6.1)Oral > 2000mg/kg Not applicable Ingredient literature (Additive formula)Dermal > 2000mg/kg Not applicable Ingredient literature (Additive formula)Inhalation > 20 mg/L Not applicable Ingredient literature (Additive formula)Eye Damage/Irritation Corrosion Category 1 Ingredient literatureSkin Damage/Irritation Corrosion Category 1C Ingredient literatureSummary: Skin and eye contact are most likely routes of exposure. Exposure causes skin burns and serious eye damage. Subchronic/Chronic Toxicity:Test Results Classification BasisSkin Sensitization Not a sensitizer Not applicable Ingredient literature.Summary: Repeated or prolonged contact causes skin burns and serious eye damage.Carcinogens - Ingredients are not listed on the NTP Report on Carcinogens, IARC Monographs or by OSHAOther data - No other toxicological information is available for this mixture.12. Ecological InformationThis material has not been tested for acute environmental effects.Persistence and degradability: Material is not persistent. All organic components > 1% are inherently biodegradable.Bio-accumulative potential: No evidence to suggest bio-accumulation will occur.Mobility: Accidental spillage may lead to penetration of soil and groundwater.13. Disposal ConsiderationsDo not contaminate water, food or feed by disposal. Pesticide wastes are acutely hazardous. Improper disposal of excess pesticide, spray, or mixture of rinsate is a violation of Federal Law. If these wastes cannot be disposed of by use according to label directions, contact your State Pesticide or Environmental Control Agency, or the hazardous waste representative at the nearest EPA Regional Office for guidance. Container Disposal: Non-refillable container. Do not reuse or refill this container. Offer for recycling if available. Triple rinse container promptly after emptying. Then offer for recycling or reconditioning, or puncture and dispose of in a sanitary landfill, or incinerate, or if allowed by state and local authorities, burn. If burned, stay out of smoke. If container is one gallon or less, wrap empty container in plastic bag and discard in trash.14. Transport InformationProper Shipping Name: Not regulated RQ - Not ApplicableShipping emergency phone: 800-424-9300Transport hazard class: N/A Hazard Label: N/APacking Group:N/A Emergency Guide No.: N/A Marine Pollutant: No15. Regulatory InformationInventory status: All components are listed on TSCA(US), EINECS/ELINCS(EU), DSL(Canada), AICS(Australia),ENCS(Japan).FIFRA: This product is a U.S. EPA Registered pesticide, EPA Reg. No. 6836-70-8155, and is subject to certain labeling requirements under Federal pesticide law. These requirements differ from the classification criteria and hazard information required for safety data sheets, and for workplace labels of non-pesticide products. The hazard information required on the pesticide label is reproduced here.DANGER: Corrosive. Causes irreversible eye damage and skin burns. Do not get in eyes, on skin or on clothing. Harmful if swallowed or absorbed through skin. Wear protective eyewear (goggles, face shield or safety glasses), protective clothing and protective gloves (rubber, chemical resistant) when handling. Wash thoroughly with soap and water after handling and before eating, drinking, chewing gum, using tobacco or using the toilet. Remove and wash contaminated clothing before reuse. The pesticide label also includes other important information, including directions for use.OSHA Hazard Communication Standard: This product meets the §1910.1200 definition of a "Hazardous Chemical". Superfund Amendments and Reauthorization Act of 1986 Title III (EPCRA) Sections 311 and 312Immediate (Acute) Health Hazard Yes Delayed (Chronic) Health Hazard NoFire Hazard No Reactive Hazard NoSudden Release of Pressure Hazard NoSuperfund Amendments and Reauthorization Act of 1986 Title III (EPCRA) Section 313*Chemicals marked with an asterisk in “3. Composition/Information on Ingredients” are subject to reporting requirements for Section 313 of Title III of the Superfund Amendments and Reauthorization Act (SARA) of 1986 and 40CFR Part 372.15. Regulatory Information (cont.)Pennsylvania/New Jersey/Massachusetts Right to KnowSee “3. Composition/Information on Ingredients” for hazardous and top five ingredients over 1% (w/w).California Proposition 65: This product does not contain a listed substance known to the State of California to cause cancer, birth defects or other reproductive harm, at levels which would require a warning under the statute.16. Other informationDate issued: 31. 12. 2014 F803-001 Revision: N/ADisclaimer: No representation or warranty, either expressed or implied, of merchantability, fitness for a particular purpose, or of any other nature, is made with respect to information concerning the product referred to in this document. The information contained herein is, to the best of our knowledge and belief, accurate. However, since the conditions of handling and use are beyond our control, it is impossible to foresee every health effect or exposure risk incurred by the use of this product. All chemicals present some degree of hazard and should be used with caution. The information and recommendations contained herein are presented in good faith. The user should review this information in conjunction with their knowledge of the application intended to determine the suitability of this product for such purpose. In no event will the supplier be responsible for any damages of any nature whatsoever, resulting from the use, reliance upon, or the misuse of this information. Furthermore, it is the direct responsibility of the user to comply with all applicable regulations governing the use and disposal of this material. Prepared by: R&D,Canberra Corporation。

美国是世界上公司法、证券法研究最为发达的国家之一，在美国法学期刊（Law Review & Journals）上每年发表400多篇以公司法和证券法为主题的论文。

自1994年开始，美国的公司法学者每年会投票从中遴选出10篇左右重要的论文，重印于Corporate Practice Commentator，至2008年，已经评选了15年，计177篇论文入选。

以下是每年入选的论文列表：2008年（以第一作者姓名音序为序）：1.Anabtawi, Iman and Lynn Stout. Fiduciary duties for activist shareholders. 60 Stan. L. Rev. 1255-1308 (2008).2.Brummer, Chris. Corporate law preemption in an age of global capital markets. 81 S. Cal. L. Rev. 1067-1114 (2008).3.Choi, Stephen and Marcel Kahan. The market penalty for mutual fund scandals. 87 B.U. L. Rev. 1021-1057 (2007).4.Choi, Stephen J. and Jill E. Fisch. On beyond CalPERS: Survey evidence on the developing role of public pension funds in corporate governance. 61 V and. L. Rev. 315-354 (2008).5.Cox, James D., Randall S. Thoma s and Lynn Bai. There are plaintiffs and…there are plaintiffs: An empirical analysis of securities class action settlements. 61 V and. L. Rev. 355-386 (2008).6.Henderson, M. Todd. Paying CEOs in bankruptcy: Executive compensation when agency costs are low. 101 Nw. U. L. Rev. 1543-1618 (2007).7.Hu, Henry T.C. and Bernard Black. Equity and debt decoupling and empty voting II: Importance and extensions. 156 U. Pa. L. Rev. 625-739 (2008).8.Kahan, Marcel and Edward Rock. The hanging chads of corporate voting. 96 Geo. L.J. 1227-1281 (2008).9.Strine, Leo E., Jr. Toward common sense and common ground? Reflections on the shared interests of managers and labor in a more rational system of corporate governance. 33 J. Corp. L. 1-20 (2007).10.Subramanian, Guhan. Go-shops vs. no-shops in private equity deals: Evidence and implications.63 Bus. Law. 729-760 (2008).2007年：1.Baker, Tom and Sean J. Griffith. The Missing Monitor in Corporate Governance: The Directors’ & Officers’ Liability Insurer. 95 Geo. L.J. 1795-1842 (2007).2.Bebchuk, Lucian A. The Myth of the Shareholder Franchise. 93 V a. L. Rev. 675-732 (2007).3.Choi, Stephen J. and Robert B. Thompson. Securities Litigation and Its Lawyers: Changes During the First Decade After the PSLRA. 106 Colum. L. Rev. 1489-1533 (2006).4.Coffee, John C., Jr. Reforming the Securities Class Action: An Essay on Deterrence and Its Implementation. 106 Colum. L. Rev. 1534-1586 (2006).5.Cox, James D. and Randall S. Thomas. Does the Plaintiff Matter? An Empirical Analysis of Lead Plaintiffs in Securities Class Actions. 106 Colum. L. Rev. 1587-1640 (2006).6.Eisenberg, Theodore and Geoffrey Miller. Ex Ante Choice of Law and Forum: An Empirical Analysis of Corporate Merger Agreements. 59 V and. L. Rev. 1975-2013 (2006).7.Gordon, Jeffrey N. The Rise of Independent Directors in the United States, 1950-2005: Of Shareholder V alue and Stock Market Prices. 59 Stan. L. Rev. 1465-1568 (2007).8.Kahan, Marcel and Edward B. Rock. Hedge Funds in Corporate Governance and Corporate Control. 155 U. Pa. L. Rev. 1021-1093 (2007).ngevoort, Donald C. The Social Construction of Sarbanes-Oxley. 105 Mich. L. Rev. 1817-1855 (2007).10.Roe, Mark J. Legal Origins, Politics, and Modern Stock Markets. 120 Harv. L. Rev. 460-527 (2006).11.Subramanian, Guhan. Post-Siliconix Freeze-outs: Theory and Evidence. 36 J. Legal Stud. 1-26 (2007). (NOTE: This is an earlier working draft. The published article is not freely available, and at SLW we generally respect the intellectual property rights of others.)2006年：1.Bainbridge, Stephen M. Director Primacy and Shareholder Disempowerment. 119 Harv. L. Rev. 1735-1758 (2006).2.Bebchuk, Lucian A. Letting Shareholders Set the Rules. 119 Harv. L. Rev. 1784-1813 (2006).3.Black, Bernard, Brian Cheffins and Michael Klausner. Outside Director Liability. 58 Stan. L. Rev. 1055-1159 (2006).4.Choi, Stephen J., Jill E. Fisch and A.C. Pritchard. Do Institutions Matter? The Impact of the Lead Plaintiff Provision of the Private Securities Litigation Reform Act. 835.Cox, James D. and Randall S. Thomas. Letting Billions Slip Through Y our Fingers: Empirical Evidence and Legal Implications of the Failure of Financial Institutions to Participate in Securities Class Action Settlements. 58 Stan. L. Rev. 411-454 (2005).6.Gilson, Ronald J. Controlling Shareholders and Corporate Governance: Complicating the Comparative Taxonomy. 119 Harv. L. Rev. 1641-1679 (2006).7.Goshen , Zohar and Gideon Parchomovsky. The Essential Role of Securities Regulation. 55 Duke L.J. 711-782 (2006).8.Hansmann, Henry, Reinier Kraakman and Richard Squire. Law and the Rise of the Firm. 119 Harv. L. Rev. 1333-1403 (2006).9.Hu, Henry T. C. and Bernard Black. Empty V oting and Hidden (Morphable) Ownership: Taxonomy, Implications, and Reforms. 61 Bus. Law. 1011-1070 (2006).10.Kahan, Marcel. The Demand for Corporate Law: Statutory Flexibility, Judicial Quality, or Takeover Protection? 22 J. L. Econ. & Org. 340-365 (2006).11.Kahan, Marcel and Edward Rock. Symbiotic Federalism and the Structure of Corporate Law.58 V and. L. Rev. 1573-1622 (2005).12.Smith, D. Gordon. The Exit Structure of V enture Capital. 53 UCLA L. Rev. 315-356 (2005).2005年：1.Bebchuk, Lucian Arye. The case for increasing shareholder power. 118 Harv. L. Rev. 833-914 (2005).2.Bratton, William W. The new dividend puzzle. 93 Geo. L.J. 845-895 (2005).3.Elhauge, Einer. Sacrificing corporate profits in the public interest. 80 N.Y.U. L. Rev. 733-869 (2005).4.Johnson, . Corporate officers and the business judgment rule. 60 Bus. Law. 439-469 (2005).haupt, Curtis J. In the shadow of Delaware? The rise of hostile takeovers in Japan. 105 Colum. L. Rev. 2171-2216 (2005).6.Ribstein, Larry E. Are partners fiduciaries? 2005 U. Ill. L. Rev. 209-251.7.Roe, Mark J. Delaware?s politics. 118 Harv. L. Rev. 2491-2543 (2005).8.Romano, Roberta. The Sarbanes-Oxley Act and the making of quack corporate governance. 114 Y ale L.J. 1521-1611 (2005).9.Subramanian, Guhan. Fixing freezeouts. 115 Y ale L.J. 2-70 (2005).10.Thompson, Robert B. and Randall S. Thomas. The public and private faces of derivative lawsuits. 57 V and. L. Rev. 1747-1793 (2004).11.Weiss, Elliott J. and J. White. File early, then free ride: How Delaware law (mis)shapes shareholder class actions. 57 V and. L. Rev. 1797-1881 (2004).2004年：1Arlen, Jennifer and Eric Talley. Unregulable defenses and the perils of shareholder choice. 152 U. Pa. L. Rev. 577-666 (2003).2.Bainbridge, Stephen M. The business judgment rule as abstention doctrine. 57 V and. L. Rev. 83-130 (2004).3.Bebchuk, Lucian Arye and Alma Cohen. Firms' decisions where to incorporate. 46 J.L. & Econ. 383-425 (2003).4.Blair, Margaret M. Locking in capital: what corporate law achieved for business organizers in the nineteenth century. 51 UCLA L. Rev. 387-455 (2003).5.Gilson, Ronald J. and Jeffrey N. Gordon. Controlling shareholders. 152 U. Pa. L. Rev. 785-843 (2003).6.Roe, Mark J. Delaware 's competition. 117 Harv. L. Rev. 588-646 (2003).7.Sale, Hillary A. Delaware 's good faith. 89 Cornell L. Rev. 456-495 (2004).8.Stout, Lynn A. The mechanisms of market inefficiency: an introduction to the new finance. 28 J. Corp. L. 635-669 (2003).9.Subramanian, Guhan. Bargaining in the shadow of takeover defenses. 113 Y ale L.J. 621-686 (2003).10.Subramanian, Guhan. The disappearing Delaware effect. 20 J.L. Econ. & Org. 32-59 (2004)11.Thompson, Robert B. and Randall S. Thomas. The new look of shareholder litigation: acquisition-oriented class actions. 57 V and. L. Rev. 133-209 (2004).2003年：1.A yres, Ian and Stephen Choi. Internalizing outsider trading. 101 Mich. L. Rev. 313-408 (2002).2.Bainbridge, Stephen M. Director primacy: The means and ends of corporate governance. 97 Nw. U. L. Rev. 547-606 (2003).3.Bebchuk, Lucian, Alma Cohen and Allen Ferrell. Does the evidence favor state competition in corporate law? 90 Cal. L. Rev. 1775-1821 (2002).4.Bebchuk, Lucian Arye, John C. Coates IV and Guhan Subramanian. The Powerful Antitakeover Force of Staggered Boards: Further findings and a reply to symposium participants. 55 Stan. L. Rev. 885-917 (2002).5.Choi, Stephen J. and Jill E. Fisch. How to fix Wall Street: A voucher financing proposal for securities intermediaries. 113 Y ale L.J. 269-346 (2003).6.Daines, Robert. The incorporation choices of IPO firms. 77 N.Y.U. L. Rev.1559-1611 (2002).7.Gilson, Ronald J. and David M. Schizer. Understanding venture capital structure: A taxexplanation for convertible preferred stock. 116 Harv. L. Rev. 874-916 (2003).8.Kahan, Marcel and Ehud Kamar. The myth of state competition in corporate law. 55 Stan. L. Rev. 679-749 (2002).ngevoort, Donald C. Taming the animal spirits of the stock markets: A behavioral approach to securities regulation. 97 Nw. U. L. Rev. 135-188 (2002).10.Pritchard, A.C. Justice Lewis F. Powell, Jr., and the counterrevolution in the federal securities laws. 52 Duke L.J. 841-949 (2003).11.Thompson, Robert B. and Hillary A. Sale. Securities fraud as corporate governance: Reflections upon federalism. 56 V and. L. Rev. 859-910 (2003).2002年：1.Allen, William T., Jack B. Jacobs and Leo E. Strine, Jr. Function over Form: A Reassessment of Standards of Review in Delaware Corporation Law. 26 Del. J. Corp. L. 859-895 (2001) and 56 Bus. Law. 1287 (2001).2.A yres, Ian and Joe Bankman. Substitutes for Insider Trading. 54 Stan. L. Rev. 235-254 (2001).3.Bebchuk, Lucian Arye, Jesse M. Fried and David I. Walker. Managerial Power and Rent Extraction in the Design of Executive Compensation. 69 U. Chi. L. Rev. 751-846 (2002).4.Bebchuk, Lucian Arye, John C. Coates IV and Guhan Subramanian. The Powerful Antitakeover Force of Staggered Boards: Theory, Evidence, and Policy. 54 Stan. L. Rev. 887-951 (2002).5.Black, Bernard and Reinier Kraakman. Delaware’s Takeover Law: The Uncertain Search for Hidden V alue. 96 Nw. U. L. Rev. 521-566 (2002).6.Bratton, William M. Enron and the Dark Side of Shareholder V alue. 76 Tul. L. Rev. 1275-1361 (2002).7.Coates, John C. IV. Explaining V ariation in Takeover Defenses: Blame the Lawyers. 89 Cal. L. Rev. 1301-1421 (2001).8.Kahan, Marcel and Edward B. Rock. How I Learned to Stop Worrying and Love the Pill: Adaptive Responses to Takeover Law. 69 U. Chi. L. Rev. 871-915 (2002).9.Kahan, Marcel. Rethinking Corporate Bonds: The Trade-off Between Individual and Collective Rights. 77 N.Y.U. L. Rev. 1040-1089 (2002).10.Roe, Mark J. Corporate Law’s Limits. 31 J. Legal Stud. 233-271 (2002).11.Thompson, Robert B. and D. Gordon Smith. Toward a New Theory of the Shareholder Role: "Sacred Space" in Corporate Takeovers. 80 Tex. L. Rev. 261-326 (2001).2001年：1.Black, Bernard S. The legal and institutional preconditions for strong securities markets. 48 UCLA L. Rev. 781-855 (2001).2.Coates, John C. IV. Takeover defenses in the shadow of the pill: a critique of the scientific evidence. 79 Tex. L. Rev. 271-382 (2000).3.Coates, John C. IV and Guhan Subramanian. A buy-side model of M&A lockups: theory and evidence. 53 Stan. L. Rev. 307-396 (2000).4.Coffee, John C., Jr. The rise of dispersed ownership: the roles of law and the state in the separation of ownership and control. 111 Y ale L.J. 1-82 (2001).5.Choi, Stephen J. The unfounded fear of Regulation S: empirical evidence on offshore securities offerings. 50 Duke L.J. 663-751 (2000).6.Daines, Robert and Michael Klausner. Do IPO charters maximize firm value? Antitakeover protection in IPOs. 17 J.L. Econ. & Org. 83-120 (2001).7.Hansmann, Henry and Reinier Kraakman. The essential role of organizational law. 110 Y ale L.J. 387-440 (2000).ngevoort, Donald C. The human nature of corporate boards: law, norms, and the unintended consequences of independence and accountability. 89 Geo. L.J. 797-832 (2001).9.Mahoney, Paul G. The political economy of the Securities Act of 1933. 30 J. Legal Stud. 1-31 (2001).10.Roe, Mark J. Political preconditions to separating ownership from corporate control. 53 Stan. L. Rev. 539-606 (2000).11.Romano, Roberta. Less is more: making institutional investor activism a valuable mechanism of corporate governance. 18 Y ale J. on Reg. 174-251 (2001).2000年：1.Bratton, William W. and Joseph A. McCahery. Comparative Corporate Governance and the Theory of the Firm: The Case Against Global Cross Reference. 38 Colum. J. Transnat’l L. 213-297 (1999).2.Coates, John C. IV. Empirical Evidence on Structural Takeover Defenses: Where Do We Stand?54 U. Miami L. Rev. 783-797 (2000).3.Coffee, John C., Jr. Privatization and Corporate Governance: The Lessons from Securities Market Failure. 25 J. Corp. L. 1-39 (1999).4.Fisch, Jill E. The Peculiar Role of the Delaware Courts in the Competition for Corporate Charters. 68 U. Cin. L. Rev. 1061-1100 (2000).5.Fox, Merritt B. Retained Mandatory Securities Disclosure: Why Issuer Choice Is Not Investor Empowerment. 85 V a. L. Rev. 1335-1419 (1999).6.Fried, Jesse M. Insider Signaling and Insider Trading with Repurchase Tender Offers. 67 U. Chi. L. Rev. 421-477 (2000).7.Gulati, G. Mitu, William A. Klein and Eric M. Zolt. Connected Contracts. 47 UCLA L. Rev. 887-948 (2000).8.Hu, Henry T.C. Faith and Magic: Investor Beliefs and Government Neutrality. 78 Tex. L. Rev. 777-884 (2000).9.Moll, Douglas K. Shareholder Oppression in Close Corporations: The Unanswered Question of Perspective. 53 V and. L. Rev. 749-827 (2000).10.Schizer, David M. Executives and Hedging: The Fragile Legal Foundation of Incentive Compatibility. 100 Colum. L. Rev. 440-504 (2000).11.Smith, Thomas A. The Efficient Norm for Corporate Law: A Neotraditional Interpretation of Fiduciary Duty. 98 Mich. L. Rev. 214-268 (1999).12.Thomas, Randall S. and Kenneth J. Martin. The Determinants of Shareholder V oting on Stock Option Plans. 35 Wake Forest L. Rev. 31-81 (2000).13.Thompson, Robert B. Preemption and Federalism in Corporate Governance: Protecting Shareholder Rights to V ote, Sell, and Sue. 62 Law & Contemp. Probs. 215-242 (1999).1999年（以第一作者姓名音序为序）：1.Bankman, Joseph and Ronald J. Gilson. Why Start-ups? 51 Stan. L. Rev. 289-308 (1999).2.Bhagat, Sanjai and Bernard Black. The Uncertain Relationship Between Board Composition and Firm Performance. 54 Bus. Law. 921-963 (1999).3.Blair, Margaret M. and Lynn A. Stout. A Team Production Theory of Corporate Law. 85 V a. L. Rev. 247-328 (1999).4.Coates, John C., IV. “Fair V alue” As an A voidable Rule of Corporate Law: Minority Discounts in Conflict Transactions. 147 U. Pa. L. Rev. 1251-1359 (1999).5.Coffee, John C., Jr. The Future as History: The Prospects for Global Convergence in Corporate Governance and Its Implications. 93 Nw. U. L. Rev. 641-707 (1999).6.Eisenberg, Melvin A. Corporate Law and Social Norms. 99 Colum. L. Rev. 1253-1292 (1999).7.Hamermesh, Lawrence A. Corporate Democracy and Stockholder-Adopted By-laws: Taking Back the Street? 73 Tul. L. Rev. 409-495 (1998).8.Krawiec, Kimberly D. Derivatives, Corporate Hedging, and Shareholder Wealth: Modigliani-Miller Forty Y ears Later. 1998 U. Ill. L. Rev. 1039-1104.ngevoort, Donald C. Rereading Cady, Roberts: The Ideology and Practice of Insider Trading Regulation. 99 Colum. L. Rev. 1319-1343 (1999).ngevoort, Donald C. Half-Truths: Protecting Mistaken Inferences By Investors and Others.52 Stan. L. Rev. 87-125 (1999).11.Talley, Eric. Turning Servile Opportunities to Gold: A Strategic Analysis of the Corporate Opportunities Doctrine. 108 Y ale L.J. 277-375 (1998).12.Williams, Cynthia A. The Securities and Exchange Commission and Corporate Social Transparency. 112 Harv. L. Rev. 1197-1311 (1999).1998年：1.Carney, William J., The Production of Corporate Law, 71 S. Cal. L. Rev. 715-780 (1998).2.Choi, Stephen, Market Lessons for Gatekeepers, 92 Nw. U. L. Rev. 916-966 (1998).3.Coffee, John C., Jr., Brave New World?: The Impact(s) of the Internet on Modern Securities Regulation. 52 Bus. Law. 1195-1233 (1997).ngevoort, Donald C., Organized Illusions: A Behavioral Theory of Why Corporations Mislead Stock Market Investors (and Cause Other Social Harms). 146 U. Pa. L. Rev. 101-172 (1997).ngevoort, Donald C., The Epistemology of Corporate-Securities Lawyering: Beliefs, Biases and Organizational Behavior. 63 Brook. L. Rev. 629-676 (1997).6.Mann, Ronald J. The Role of Secured Credit in Small-Business Lending. 86 Geo. L.J. 1-44 (1997).haupt, Curtis J., Property Rights in Firms. 84 V a. L. Rev. 1145-1194 (1998).8.Rock, Edward B., Saints and Sinners: How Does Delaware Corporate Law Work? 44 UCLA L. Rev. 1009-1107 (1997).9.Romano, Roberta, Empowering Investors: A Market Approach to Securities Regulation. 107 Y ale L.J. 2359-2430 (1998).10.Schwab, Stewart J. and Randall S. Thomas, Realigning Corporate Governance: Shareholder Activism by Labor Unions. 96 Mich. L. Rev. 1018-1094 (1998).11.Skeel, David A., Jr., An Evolutionary Theory of Corporate Law and Corporate Bankruptcy. 51 V and. L. Rev. 1325-1398 (1998).12.Thomas, Randall S. and Martin, Kenneth J., Should Labor Be Allowed to Make Shareholder Proposals? 73 Wash. L. Rev. 41-80 (1998).1997年：1.Alexander, Janet Cooper, Rethinking Damages in Securities Class Actions, 48 Stan. L. Rev. 1487-1537 (1996).2.Arlen, Jennifer and Kraakman, Reinier, Controlling Corporate Misconduct: An Analysis of Corporate Liability Regimes, 72 N.Y.U. L. Rev. 687-779 (1997).3.Brudney, Victor, Contract and Fiduciary Duty in Corporate Law, 38 B.C. L. Rev. 595-665 (1997).4.Carney, William J., The Political Economy of Competition for Corporate Charters, 26 J. Legal Stud. 303-329 (1997).5.Choi, Stephen J., Company Registration: Toward a Status-Based Antifraud Regime, 64 U. Chi. L. Rev. 567-651 (1997).6.Fox, Merritt B., Securities Disclosure in a Globalizing Market: Who Should Regulate Whom. 95 Mich. L. Rev. 2498-2632 (1997).7.Kahan, Marcel and Klausner, Michael, Lockups and the Market for Corporate Control, 48 Stan. L. Rev. 1539-1571 (1996).8.Mahoney, Paul G., The Exchange as Regulator, 83 V a. L. Rev. 1453-1500 (1997).haupt, Curtis J., The Market for Innovation in the United States and Japan: V enture Capital and the Comparative Corporate Governance Debate, 91 Nw. U.L. Rev. 865-898 (1997).10.Skeel, David A., Jr., The Unanimity Norm in Delaware Corporate Law, 83 V a. L. Rev. 127-175 (1997).1996年：1.Black, Bernard and Reinier Kraakman A Self-Enforcing Model of Corporate Law, 109 Harv. L. Rev. 1911 (1996)2.Gilson, Ronald J. Corporate Governance and Economic Efficiency: When Do Institutions Matter?, 74 Wash. U. L.Q. 327 (1996)3. Hu, Henry T.C. Hedging Expectations: "Derivative Reality" and the Law and Finance of the Corporate Objective, 21 J. Corp. L. 3 (1995)4.Kahan, Marcel & Michael Klausner Path Dependence in Corporate Contracting: Increasing Returns, Herd Behavior and Cognitive Biases, 74 Wash. U. L.Q. 347 (1996)5.Kitch, Edmund W. The Theory and Practice of Securities Disclosure, 61 Brooklyn L. Rev. 763 (1995)ngevoort, Donald C. Selling Hope, Selling Risk: Some Lessons for Law From Behavioral Economics About Stockbrokers and Sophisticated Customers, 84 Cal. L. Rev. 627 (1996)7.Lin, Laura The Effectiveness of Outside Directors as a Corporate Governance Mechanism: Theories and Evidence, 90 Nw. U.L. Rev. 898 (1996)lstein, Ira M. The Professional Board, 50 Bus. Law 1427 (1995)9.Thompson, Robert B. Exit, Liquidity, and Majority Rule: Appraisal's Role in Corporate Law, 84 Geo. L.J. 1 (1995)10.Triantis, George G. and Daniels, Ronald J. The Role of Debt in Interactive Corporate Governance. 83 Cal. L. Rev. 1073 (1995)1995年：公司法：1.Arlen, Jennifer and Deborah M. Weiss A Political Theory of Corporate Taxation,. 105 Y ale L.J. 325-391 (1995).2.Elson, Charles M. The Duty of Care, Compensation, and Stock Ownership, 63 U. Cin. L. Rev. 649 (1995).3.Hu, Henry T.C. Heeding Expectations: "Derivative Reality" and the Law and Finance of the Corporate Objective, 73 Tex. L. Rev. 985-1040 (1995).4.Kahan, Marcel The Qualified Case Against Mandatory Terms in Bonds, 89 Nw. U.L. Rev. 565-622 (1995).5.Klausner, Michael Corporations, Corporate Law, and Networks of Contracts, 81 V a. L. Rev. 757-852 (1995).6.Mitchell, Lawrence E. Cooperation and Constraint in the Modern Corporation: An Inquiry Into the Causes of Corporate Immorality, 73 Tex. L. Rev. 477-537 (1995).7.Siegel, Mary Back to the Future: Appraisal Rights in the Twenty-First Century, 32 Harv. J. on Legis. 79-143 (1995).证券法：1.Grundfest, Joseph A. Why Disimply? 108 Harv. L. Rev. 727-747 (1995).2.Lev, Baruch and Meiring de V illiers Stock Price Crashes and 10b-5 Damages: A Legal Economic, and Policy Analysis, 47 Stan. L. Rev. 7-37 (1994).3.Mahoney, Paul G. Mandatory Disclosure as a Solution to Agency Problems, 62 U. Chi. L. Rev. 1047-1112 (1995).4.Seligman, Joel The Merits Do Matter, 108 Harv. L. Rev. 438 (1994).5.Seligman, Joel The Obsolescence of Wall Street: A Contextual Approach to the Evolving Structure of Federal Securities Regulation, 93 Mich. L. Rev. 649-702 (1995).6.Stout, Lynn A. Are Stock Markets Costly Casinos? Disagreement, Mark Failure, and Securities Regulation, 81 V a. L. Rev. 611 (1995).7.Weiss, Elliott J. and John S. Beckerman Let the Money Do the Monitoring: How Institutional Investors Can Reduce Agency Costs in Securities Class Actions, 104 Y ale L.J. 2053-2127 (1995).1994年：公司法：1.Fraidin, Stephen and Hanson, Jon D. Toward Unlocking Lockups, 103 Y ale L.J. 1739-1834 (1994)2.Gordon, Jeffrey N. Institutions as Relational Investors: A New Look at Cumulative V oting, 94 Colum. L. Rev. 124-192 (1994)3.Karpoff, Jonathan M., and Lott, John R., Jr. The Reputational Penalty Firms Bear From Committing Criminal Fraud, 36 J.L. & Econ. 757-802 (1993)4.Kraakman, Reiner, Park, Hyun, and Shavell, Steven When Are Shareholder Suits in Shareholder Interests?, 82 Geo. L.J. 1733-1775 (1994)5.Mitchell, Lawrence E. Fairness and Trust in Corporate Law, 43 Duke L.J. 425- 491 (1993)6.Oesterle, Dale A. and Palmiter, Alan R. Judicial Schizophrenia in Shareholder V oting Cases, 79 Iowa L. Rev. 485-583 (1994)7. Pound, John The Rise of the Political Model of Corporate Governance and Corporate Control, 68 N.Y.U. L. Rev. 1003-1071 (1993)8.Skeel, David A., Jr. Rethinking the Line Between Corporate Law and Corporate Bankruptcy, 72 Tex. L. Rev. 471-557 (1994)9.Thompson, Robert B. Unpacking Limited Liability: Direct and V icarious Liability of Corporate Participants for Torts of the Enterprise, 47 V and. L. Rev. 1-41 (1994)证券法：1.Alexander, Janet Cooper The V alue of Bad News in Securities Class Actions, 41 UCLA L.Rev. 1421-1469 (1994)2.Bainbridge, Stephen M. Insider Trading Under the Restatement of the Law Governing Lawyers, 19 J. Corp. L. 1-40 (1993)3.Black, Bernard S. and Coffee, John C. Jr. Hail Britannia?: Institutional Investor Behavior Under Limited Regulation, 92 Mich. L. Rev. 1997-2087 (1994)4.Booth, Richard A. The Efficient Market, portfolio Theory, and the Downward Sloping Demand Hypothesis, 68 N.Y.U. L. Rev. 1187-1212 (1993)5.Coffee, John C., Jr. The SEC and the Institutional Investor: A Half-Time Report, 15 Cardozo L. Rev 837-907 (1994)6.Fox, Merritt B. Insider Trading Deterrence V ersus Managerial Incentives: A Unified Theory of Section 16(b), 92 Mich. L. Rev. 2088-2203 (1994)7.Grundfest, Joseph A. Disimplying Private Rights of Action Under the Federal Securities Laws: The Commission's Authority, 107 Harv. L. Rev. 961-1024 (1994)8.Macey, Jonathan R. Administrative Agency Obsolescence and Interest Group Formation: A Case Study of the SEC at Sixty, 15 Cardozo L. Rev. 909-949 (1994)9.Rock, Edward B. Controlling the Dark Side of Relational Investing, 15 Cardozo L. Rev. 987-1031 (1994)。

美国FDA福迪安一氧化氮片福迪安一氧化氮的7大优势1、美国原装进口采用国际先进配方，结合中国人健康状况而设计，由GMP药厂生产，通过ISO9001国际质量认证、国际食品安全管理体系认证，质量安全有保证。

2、安全无副作用绿色天然产品，纯植物萃取，没有任何毒副作用，服用更放心。

3、、科学配方，保障持续足量产生一氧化氮L—精氨酸是产生一氧化氮的基础物质，可以在L—瓜氨酸和几种关键的抗氧化剂的协同作用下，让人体产生大量的一氧化氮。

福迪安一氧化氮同时含有L—精氨酸和L—瓜氨酸，不仅能使机体稳定，还能很好的发挥对心脑健康的效果。

4、与抗氧化剂合用，保持NO的稳定、延长时效福迪安一氧化氮片含有原花青素、维生素E、维生素C三种超强抗氧化及，能很好的保护已经生成的NO，免除自由基侵扰，最大程度的延长NO活动及有效时间的效果。

5、萃取技术萃取物在生产工艺中的纯化阶段，一般厂家采用“化学断裂键法”脱离无效基团，不但产量低，脱离不彻底，而且还会引入化学杂质。

产生毒副作用。

本品采用生物发酵酶切技术，用限制性内切酶去切割萃取物的DNA片断。

这种酶会识别DNA的双链互补螺旋结构，专一性定向酶切。

不但纯度高，最大限度的脱离无效基团而且安全。

不引入任何杂质。

6、智能吸收途径——等渗跨膜转动提高技术药物在人体吸收的过程中，细胞间的转动可分为被动转运和主动转运两种方式。

被动转动呈浓度梯度转动，不耗能。

主动转运是需要载体及能量的跨膜转运需耗能。

由于NO不稳定性，使它对细胞间的跨膜转运条件要求十分苛刻。

当被动转运不能实现时，如进行主动耗能转运。

就极易破坏其结构而失效。

所以一般产品具有疗效部位的局限性，不能深入细胞组织。

而本技术加入等渗因子，智能识别并调节等渗转运条件。

提升第二信使的跨膜转运速度，使生物利用率高达96%以上，为目前吸收率及利用率最高的产品。

7、L-AC速效缓释技术NO的两大有效成分：L-精氨酸的作用是在机体内生成NO迅速起效。

专利名称：乙酰辅酶A羧化酶抑制剂用于治疗寻常痤疮的用途专利类型：发明专利
发明人：W·P·埃斯勒,G·E·索南伯格
申请号：CN201480049771.8
申请日：20140829
公开号：CN105530940A
公开日：
20160427
专利内容由知识产权出版社提供
摘要：本发明涉及治疗和/或预防患者的痤疮的方法，其包括向需要该治疗的患者施用治疗上有效量的乙酰辅酶A羧化酶(ACC)抑制剂或其药学上可接受的盐的步骤。

申请人：辉瑞大药厂
地址：美国纽约州
国籍：US
代理机构：中国国际贸易促进委员会专利商标事务所
代理人：李华英
更多信息请下载全文后查看。